Sea King Biological development 139 million shares raise 1.4 billion

Sea King Biology (000078) February 17 Evening Notice that the company's board of directors to consider the adoption of the "Company's Non-public offering of shares program," the company's proposed non-public offering of not more than 139 million shares, the issue price is not less than 10.37 yuan/share, the total amount of fund-raising not more than 1.443 billion yuan. The company announced on the same day that the company intends to invest 1.102 billion yuan, in Shandong Weihai, Shandong Heze, Shandong Zaozhuang, Henan Nanyang, Hubei Xiaogan Five set up a subsidiary to build Sunshine Centralized distribution center. In addition, the company intends to subsidiary Shenzhen Hai Wang Pharmaceutical Co., Ltd. to increase the capital of not more than 175 million yuan, for the Sea King pharmaceutical solid preparation production line project and anti-tumor freeze-dry workshop project; to the subsidiary of Hangzhou Hai Wang Bioengineering Co.